Immunoblot analysis of Hh content from different samples of MVs. (A) MVs generated from CEM T cells treated with PHA/PMA/act D (lanes 1 and 2, from 2 independent preparations), PHA/act D (lane 3), PMA (lanes 4 and 5, from 2 independent preparations), PHA (lanes 6 and 7, from 2 independent preparations), or act D (lanes 8 and 9, from 2 independent preparations). (B) MVs retrieved in vivo circulating in human peripheral blood (lanes 1 and 4) and MVs generated from lymphocytes treated with PHA/PMA/act D (lanes 2 and 5) or act D (lanes 3 and 6), from healthy (1-3) or diabetic individuals (4-6). Three determinations yielding similar results were performed. In panels A and B a β-actin control was included.